| A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens J Sun, MD Masterman-Smith, NA Graham, J Jiao, J Mottahedeh, DR Laks, ... Cancer research 70 (15), 6128-6138, 2010 | 118 | 2010 |
| A fully human scFv phage display library for rapid antibody fragment reformatting K Li, KA Zettlitz, J Lipianskaya, Y Zhou, JD Marks, P Mallick, RE Reiter, ... Protein Engineering, Design and Selection 28 (10), 307-316, 2015 | 37 | 2015 |
| Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments K Li, R Tavaré, KA Zettlitz, SM Mumenthaler, P Mallick, Y Zhou, JD Marks, ... Molecular cancer therapeutics 13 (11), 2607-2617, 2014 | 37 | 2014 |
| Dual transcript and protein quantification in a massive single cell array S Park, JY Lee, S Hong, SH Lee, IK Dimov, H Lee, S Suh, Q Pan, K Li, ... Lab on a Chip 16 (19), 3682-3688, 2016 | 22 | 2016 |
| High avidity IgM-based CD20xCD3 bispecific antibody (IGM-2323) for enhanced T-cell dependent killing with minimal cytokine release R Baliga, K Li, M Manlusoc, P Hinton, D Ng, M Tran, B Shan, H Lu, A Saini, ... Blood 134, 1574, 2019 | 11 | 2019 |
| IGM-2323: High Avidity IgM-based CD20 x CD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release R Baliga, K Li, M Manlusoc, PR Hinton, DC Ng, M Tran, B Shan, H Lu, ... Abstract 1574, 7-10, 2019 | 6 | 2019 |
| Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy NJ Bangayan, L Wang, G Burton Sojo, M Noguchi, D Cheng, L Ta, ... Proceedings of the National Academy of Sciences 120 (47), e2312374120, 2023 | 5 | 2023 |
| Igm-2644, a novel CD38xCD3 bispecific IgM T cell engager demonstrates potent efficacy on myeloma cells with an improved preclinical safety profile K Li, R Yun, M Chai, P Yakkundi, R Rosete, G Li, L Liu, D Ng, PR Hinton, ... Blood 140 (Supplement 1), 6010-6011, 2022 | 5 | 2022 |
| A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release R Baliga, K Li, M Manlusoc, PR Hinton, DC Ng, MH Tran, B Shan, H Lu, ... Cancer Res 80 (16 Supplement), 5664-5664, 2020 | 3 | 2020 |
| Fully human antibodies and fragments recognizing human c-Met AM Wu, LI Keyu US Patent 10,407,503, 2019 | 3 | 2019 |
| Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanisms K Li, R Yun, M Chai, P Yakkundi, R Rosete, G Li, L Liu, M Li, D Santos, ... Cancer Res 83, 2959, 2023 | 1 | 2023 |
| High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing KC Hart, K Logronio, M Li, P Yakkundi, M Manlusoc, K Li, PR Hinton, ... Cancer Res 82, 4179, 2022 | 1 | 2022 |
| 841P IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas K Li, MF Kotturi, M Manlusoc, R Yun, PR Hinton, K Logronio, R Baliga, ... Annals of Oncology 32, S778-S779, 2021 | 1 | 2021 |
| Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323). B Keyt, R Baliga, K Li, M Manlusoc, P Hinton, D Ng, M Tran, B Shan, H Lu, ... Journal of Clinical Oncology 38 (15_suppl), e15007-e15007, 2020 | 1 | 2020 |
| IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma KC Hart, D Santos, K Li, R Yun, M Chai, A Kabai, G Li, P Yakkundi, ... Cancer Research 84 (6_Supplement), 1237-1237, 2024 | | 2024 |
| Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity J Xue, K Li, P Yakkundi, P Chadasama, T Mao, Z Malik, V Rao, ... Cancer Research 84 (6_Supplement), 6726-6726, 2024 | | 2024 |
| 1174 Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity K Li, J Xue, D Pandya, P Yakkundi, G Li, K Mai, N Hanna, Z Ye, R Rosete, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| P-047 Trial in progress: an open-label, multicenter, phase 1 study for IGM-2644 in participants with relapsed and/or refractory multiple myeloma (RRMM) R Funke, H Schade, J Berdeja, K Li, M Kotturi, G Hernandez, Y Guan, ... Clinical Lymphoma Myeloma and Leukemia 23, S60-S61, 2023 | | 2023 |
| P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA MK Leabman, G Hernandez, CM Ng, J Tang, D Pandya, KC Hart, K Li, ... HemaSphere 6, 1161-1162, 2022 | | 2022 |
| Development of fully humanized N-cadherin monoclonal antibodies for treatment of castration resistant prostate cancer EA Kono, N Kobayashi, K Zettlitz, K Li, J Yamashiro, C Wang, A Wu, ... Cancer Research 78 (13_Supplement), 1775-1775, 2018 | | 2018 |
Anna M. WuProfessor and Chair, Immunology & Theranostics, City of Hope在 coh.org 的电子邮件经过验证
